Judgment of the Court (Fourth Chamber) of 22 December 2010 – Commission v Poland

(Case C-385/08)

Failure of a Member State to fulfil obligations – Accession of new Member States – Marketing authorisations for medicinal products that are generics of the reference product Plavix – Conditional decisions authorising the marketing of pharmaceutical products – Infringement of the acquis

1.                     Actions for failure to fulfil obligations – Subject-matter of the dispute (Art. 226 EC) (see paras 28-33)

2.                     Procedure – Application initiating proceedings – Formal requirements – Identification of the subject-matter of the dispute – Brief summary of the pleas in law on which the application is based – Unambiguous wording of the form of order sought by the applicant (Rules of Procedure of the Court of Justice, Art. 38(1)(c)) (see paras 34-37)

3.                     Approximation of laws – Medicinal products for human use – Marketing authorisation (Treaty of Accession 2003, Arts 2 and 24 and Annex XII, Chapter 1, para. 5; European Parliament and Council Regulation No 726/2004, Arts 89 and 90; Council Regulation No 2309/93, Art. 13(4); European Parliament and Council Directive 2001/83, Art. 6(1)) (see paras 62-70, 77-82, operative part)

Re:

Operative part

The Court:

–        by retaining in force the decisions of the Minister for Health concerning marketing authorisations for medicinal products that are generics of the reference product Plavix, and

–        by placing and keeping on the market, after 1 May 2004, medicinal products whose marketing authorisation was not issued in accordance with Article 6(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use,

the Republic of Poland has failed to fulfil its obligations, as regards the first indent above, under Article 6(1) of Directive 2001/83, in conjunction with Article 13(4) of Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products and with Articles 89 and 90 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency and, as regards the second indent above, under Article 6(1) of Directive 2001/83;